Clinical trials located in

Boadilla del Monte

Boadilla del Monte city is located in Spain. Currently, 8 clinical trials are being conducted in this city.

Boadilla del Monte, located in the metropolitan area of Madrid, Spain, is known for its rich history and modern development. Originally a humble agricultural village, it has transformed into one of the wealthiest municipalities in the country. The city boasts the 18th-century Palacio del Infante Don Luis, a testament to its historical significance, surrounded by vast gardens. Boadilla del Monte seamlessly blends its historical roots with contemporary living, featuring state-of-the-art facilities and a high quality of life for its residents.

  • CT-EU-00041358

    Continued Parsaclisib treatment for B-cell cancer patients

    This is a phase II clinical trial focused on providing continuation of treatment with a drug called parsaclisib to people diagnosed with B-cell malignancies. The main goal of this study is to expand the treatment regimen established in the previous study. Study participants will receive parsaclisib as a stand-alone therapy (monotherapy) or in combination with other therapeutic agents, which may include itacitinib, ruxolitinib or ibrutinib. The study aims to facilitate participants’ ongoing care and contribute to the broader field of medical research by collecting data on the effectiveness and safety of prolonged use of parsaclisib.

    • Ibrutinib
    • Ruxolitinib
    • Itacitinib
    • Parsaclisib
  • Comparison of different treatments for follicular lymphoma

    This study involves comparing two treatments for a condition known as follicular or marginal zone lymphoma, both of which are types of cancer affecting lymph cells. The first treatment combines zanubrutinib with an antibody called Anti-CD20, while the second treatment involves lenalidomide and rituximab. These treatments are intended for patients who have not responded or have stopped responding to conventional treatment. One of the primary objectives of the study is to determine which treatment is more effective in preventing the cancer from progressing, referred to as progression-free survival. Additionally, the study aims to assess the impact of these treatments on the patients’ quality of life, evaluating various aspects through questionnaires related to physical and emotional well-being, symptoms, and the ability to perform normal activities.

    • Zanubrutinib
    • Obinutuzumab
    • Lenalidomide
    • Rituximab
  • Study on dazostinag & pembrolizumab for advanced solid tumors

    The purpose of this study is to test a new drug called dazostinag. A study is being conducted to see whether this drug is helpful in adults with advanced forms of solid cancer. Some people are given dazostinag alone, while others are given it with another medicine called pembrolizumab. Scientists’ focus here is on finding out whether these drugs cause any side effects, and finding out what the maximum dose is that people can take without serious side effects. The study consists of two parts, including a dose escalation phase and a dose escalation phase. In the first part, the dose of dazostinag will be gradually increased, given alone or in combination with pembrolizumab. In the second part, Dazostinag will be tested with pembrolizumab and other anticancer drugs. This section will focus on patients with specific cancers that are difficult to remove or have spread to other parts of the body.

    • Dazostinag
    • Platinum
    • Pembrolizumab
    • 5-Fluorouracil
  • Examining apixaban treatment for venous thromboembolism

    This trial aims to evaluate the safety and efficacy of the medication Apixaban in the treatment of children with Venous Thromboembolism (VTE), a condition characterized by the formation of blood clots in the veins. Apixaban, functioning as a specialized agent, is intended to dissolve these clots. The primary objective of the trial is to assess the effectiveness of Apixaban in this regard. The evaluation will involve monitoring for any instances of major or minor bleeding events that may be attributed to the use of Apixaban, as well as investigating the recurrence of blood clots. Additionally, the concentration of Apixaban in the body and Anti-Xa Levels will be examined to further understand the pharmacokinetics of the medication.

    • Apixaban
  • CT-EU-00036742

    Monitoring RSV vaccine safety in post-vaccination pregnancies

    This study tracks the safety of the RSVPreF3 vaccine in women who had it during previous pregnancies. It’s focused on women who are pregnant again after receiving the vaccine and will assess the health of both mothers and their babies. The study’s main aim is to understand any potential impacts of the vaccine on pregnancy outcomes and infant health. This research is important as it provides vital information on the safety of RSV vaccines in pregnant women, contributing to public health knowledge.

  • Study of new drugs in acute lymphoblastic leukemia

    This clinical trial focuses on improving treatment strategies for acute lymphoblastic leukemia (ALL) in a diverse age group, from infants to young adults up to 45 years old. The study combines standard treatments with new drugs, for example, Inotuzumab Ozogamicin and Blinatumomab. The trial aims to tailor treatment to individual patient needs and reduce toxicity while maintaining treatment quality. By carefully monitoring event- and disease-free survival rates, as well as minimal residual disease responses, the trial aims to improve the standard of care for ALL and improve both survival outcomes and patient quality of life.

    • Inotuzumab Ozogamicin
    • 6-tioguanine
    • Blinatumomab
    • Imatinib
    • Dexamethasone
    • Vincristine
    • Doxorubicin
  • Exploring sacituzumab govitecan for HER2-negative breast cancer care

    This study is evaluating a new treatment for patients with a certain type of breast cancer (HER2-negative) who have not had a complete response to initial chemotherapy. Participants are randomly assigned to receive the investigational drug sacituzumab govitecan or a treatment of their physician’s choice, which may be another type of chemotherapy with capecitabinalub, carboplatin or cisplatin. The study is designed to compare the effectiveness of these approaches in preventing cancer recurrence. Patients may also receive hormone therapy if needed. Patients’ safety and response to treatment are being closely monitored throughout the study.

    • Sacituzumab govitecan
    • Carboplatin
    • Cisplatin
    • Capecitabine
  • Pediatric trial assessing apixaban for venous thromboembolism

    This is a trial to evaluate the effectiveness and safety of a medicine called apixaban in children who need anticoagulation treatment due to venous thromboembolism (VTE), a condition where blood clots form in the vein. The study aims to describe how well apixaban works in treating VTE in children compared to the standard treatments. The standard treatments may include other anti-coagulants such as unfractionated heparin, low molecular weight heparin, or a vitamin K antagonist. Apixaban will be given to children from birth to less than 18 years old, based on a weight-tiered regimen. This research is key to understanding the best possible treatment for children dealing with VTE, and participants’ safety will be closely monitored throughout the study.

    • Apixaban

See more clinical trials in other cities in Spain: